Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Proper use of prostate specific antigen]

Y Barthélémy1, D Chopin, C C Abbou

  • 1Service d'urologie, hôpital Henri-Mondor, Créteil.

La Revue Du Praticien
|March 1, 1994
PubMed
Summary

Prostate specific antigen (PSA) is a key biomarker for prostate cancer detection and staging. Elevated PSA levels, particularly when monitored over time and correlated with clinical findings, aid in diagnosing and managing prostate carcinoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective study comparing the conventional and same-day strategies to diagnose pulmonary tuberculosis.

Medecine et maladies infectieuses·2019
Same author

[Influenzae and pneumococcal vaccination rate in an internal medicine ward].

La Revue de medecine interne·2018
Same author

Anterior lumbar sagittal alignment after anterior or lateral interbody fusion.

Orthopaedics & traumatology, surgery & research : OTSR·2017
Same author

Report from the 2014 Scoliosis Research Society Travelling Fellowship.

Spine deformity·2016
Same author

Reduction and fusion in high-grade L5-S1 spondylolisthesis by a single posterior approach. Results in 50 patients.

Orthopaedics & traumatology, surgery & research : OTSR·2016
Same author

Evolution of adolescent idiopathic scoliosis: results of a multicenter study at 20 years' follow-up.

Orthopaedics & traumatology, surgery & research : OTSR·2015

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Context:

  • Prostate specific antigen (PSA) is a crucial biomarker for prostatic carcinoma, secreted by prostatic epithelial cells.
  • PSA levels in blood are clinically accessible, with two main tests: Tandem test R (radioimmunological) and Pros check (immunoenzymatic, more sensitive).
  • PSA levels correlate with prostate tissue mass (hyperplasia, cancer) and are vital for disease detection and monitoring.

Purpose:

  • To evaluate the clinical utility of Prostate Specific Antigen (PSA) in diagnosing, staging, and monitoring prostate carcinoma.
  • To compare the diagnostic performance of different PSA testing methods.
  • To establish the role of PSA in predicting treatment response and recurrence.

Summary:

  • PSA testing aids in prostate cancer detection, with higher predictive values at PSA > 4 ng/mL (49%) and PSA > 10 ng/mL (75%).
  • Biopsies remain essential for definitive diagnosis; rising PSA post-biopsy suggests malignancy.
  • PSA levels correlate with cancer stage (e.g., <15 ng/mL for low stage, >75 ng/mL for node-positive probability) and are crucial for monitoring treatment efficacy and detecting recurrence.

Impact:

  • PSA testing significantly improves early detection and management strategies for prostate cancer.
  • Monitoring PSA levels post-treatment is essential for assessing therapeutic response and identifying recurrence.
  • Standardized PSA testing protocols enhance diagnostic accuracy and patient outcomes in prostate cancer care.

Related Experiment Videos